Artivion (NYSE:AORT) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Artivion (NYSE:AORTFree Report) in a research report sent to investors on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $34.00 price objective on the stock.

A number of other analysts have also issued reports on AORT. Oppenheimer lifted their price target on Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $31.80.

Read Our Latest Research Report on AORT

Artivion Trading Up 0.5 %

AORT stock opened at $31.38 on Tuesday. Artivion has a 12-month low of $16.48 and a 12-month high of $32.33. The business’s 50-day moving average is $29.40 and its 200 day moving average is $27.41. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of -1,568.75 and a beta of 1.74.

Insider Transactions at Artivion

In related news, SVP Jean F. Holloway sold 8,070 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the completion of the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now owns 33,503 shares in the company, valued at $1,005,090. This trade represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,017 shares of company stock worth $600,007 in the last quarter. Company insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Calamos Advisors LLC boosted its position in Artivion by 113.7% in the 4th quarter. Calamos Advisors LLC now owns 63,029 shares of the company’s stock valued at $1,802,000 after buying an additional 33,541 shares during the period. R Squared Ltd acquired a new position in Artivion during the 4th quarter worth $39,000. KBC Group NV increased its holdings in Artivion by 80.4% during the 4th quarter. KBC Group NV now owns 2,813 shares of the company’s stock worth $80,000 after purchasing an additional 1,254 shares during the period. GAMMA Investing LLC raised its holdings in Artivion by 21.8% in the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock valued at $79,000 after acquiring an additional 497 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Artivion by 394.9% in the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock worth $2,606,000 after acquiring an additional 78,120 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Read More

Analyst Recommendations for Artivion (NYSE:AORT)

Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.